You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
食衛局:復星供港疫苗將於歐洲生產 科興北京製疫苗首批明年1月到港
阿思達克 12-14 09:35
食衛局發言人指,政府與復星醫藥(02196.HK)達成協議,將會取得最多750萬劑由復星與德國藥廠BioNTech(BNTX.US)合作研發的mRNA疫苗(即BNT162b2),供港的疫苗將於歐洲生產。第一批100萬劑量預計最快可於明年第一季交付。

發言人指,就有關採購協議合約安排復星醫藥為德國BioNTech在中國的戰略合作夥伴,雙方將共同在中國大陸及港澳台地區開發、商業化基於BioNTech專有的mRNA技術研發、針對新冠病毒的mRNA疫苗產品。根據協議約定,為本次合作之開發、商業化目的,復星醫藥產業將負責推進該產品於中國的臨床試驗、上市申請、市場銷售;BioNTech將負責提供區域內臨床試驗申請所需的技術材料和臨床前研究資料、配合區域內臨床試驗,並供應該等臨床試驗及市場銷售所需的產品。

截至目前,BioNTech研發的mRNA核酸疫苗BNT162b2已獲英國批核緊急使用及加拿大衛生部門批核使用,而輝瑞(PFE.US)為德國BioNTech mRNA核酸疫苗中國以外區域的合作夥伴。

至於由科興向香港提供的疫苗,根據科興提供的資料,有關疫苗在北京大興區生產,第一批100萬劑量最快可望於明年一月到港。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account